InvestSMART

Chimeric Therapeutics Limited (ASX: CHM) - Announcements

- Current share price for CHM : $0.039

ASX company news and announcements for Chimeric Therapeutics Limited (CHM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Chimeric Therapeutics Limited (CHM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Chimeric Therapeutics Limited (CHM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Chimeric Therapeutics Limited (CHM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2 Trading Halt 16 May 2025 9:02AM $0.008 $0.039 risen by 387.50%
$2 ADVENT-AML Phase 1B clinical trial update 15 May 2025 1:08PM $0.005 $0.039 risen by 680%
$2 Trading Halt 15 May 2025 12:04PM $0.005 $0.039 risen by 680%
$2 Pause in Trading 15 May 2025 10:18AM $0.005 $0.039 risen by 680%
$2 Application for quotation of securities - CHM 9 May 2025 4:46PM $0.005 $0.039 risen by 680%
$2 Change in substantial holding 1 May 2025 5:25PM $0.005 $0.039 risen by 680%
$2 Change of Director's Interest Notice PH 1 May 2025 5:25PM $0.005 $0.039 risen by 680%
$2 Change of Director's Interest Notice 1 May 2025 5:24PM $0.005 $0.039 risen by 680%
$2 Application for quotation of securities - CHM 30 Apr 2025 8:48AM $0.005 $0.039 risen by 680%
$2 Application for quotation of securities - CHM 30 Apr 2025 8:47AM $0.005 $0.039 risen by 680%
$2 EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL 24 Apr 2025 12:26PM $0.005 $0.039 risen by 680%
$2 Completion of Entitlement Offer 24 Apr 2025 9:59AM $0.005 $0.039 risen by 680%
$2 Quarterly Activities/Appendix 4C Cash Flow Report 23 Apr 2025 9:57AM $0.005 $0.039 risen by 766.67%
$2 Letter to CHMAAC option holders 4 Apr 2025 8:28AM $0.004 $0.039 risen by 875%
$2 Update - Proposed issue of securities - CHM 3 Apr 2025 9:03AM $0.005 $0.039 risen by 680%
$2 Entitlement Offer closing date extended to 22 April 2025 3 Apr 2025 8:25AM $0.005 $0.039 risen by 680%
$2 Option Exp 19 Dec 2025 Range of Units and Top 20 Holders 2 Apr 2025 9:07AM $0.004 $0.039 risen by 875%
$2 Application for quotation of securities - CHM 2 Apr 2025 9:00AM $0.004 $0.039 risen by 875%
$2 US patent allowed for CHM CDH17 technology 25 Mar 2025 9:49AM $0.005 $0.039 risen by 680%
$2 Entitlement Offer Documents 25 Mar 2025 9:09AM $0.005 $0.039 risen by 680%
$2 Proposed issue of securities - CHM 18 Mar 2025 10:06AM $0.006 $0.039 risen by 550%
$2 Update - Proposed issue of securities - CHM 18 Mar 2025 9:55AM $0.006 $0.039 risen by 550%
$2 Prospectus 18 Mar 2025 9:42AM $0.006 $0.039 risen by 550%
$2 Entitlement Offer to raise approximately $3.2 million 18 Mar 2025 9:39AM $0.006 $0.039 risen by 550%
$2 Application for quotation of securities - CHM 17 Mar 2025 5:11PM $0.006 $0.039 risen by 550%

126 - 150 of 640 results

Page 6 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.